| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
KUN50259 targets D-amino acid oxidase (DAAO), a flavin adenine dinucleotide (FAD)-containing enzyme. It acts as a potent inhibitor, blocking the enzyme's activity. By inhibiting DAAO, it prevents the breakdown of D-amino acids, which can modulate neurotransmission and have therapeutic effects in conditions such as schizophrenia and pain.
|
|---|---|
| ln Vitro |
In vitro, KUN50259 is a potent inhibitor of DAAO with an IC50 of 0.12 μM. This high potency makes it a valuable tool for studying the role of DAAO in various biological processes. Its inhibitory activity can be confirmed in enzymatic assays using purified DAAO enzyme.
|
| ln Vivo |
In vivo activity data for KUN50259 is limited. As a potent DAAO inhibitor, it is expected to have effects on D-amino acid levels and neurotransmission in the brain. It has potential applications in the study of neurological and psychiatric disorders where DAAO is implicated. However, specific in vivo study details are not well-documented.
|
| Enzyme Assay |
KUN50259 is evaluated in cell-free enzymatic assays using purified DAAO enzyme. The compound is incubated with DAAO and a substrate, such as D-alanine, and the inhibition of enzyme activity is measured. IC50 values are determined to quantify the potency of DAAO inhibition. The assay can be performed using a coupled enzyme system to detect the production of hydrogen peroxide.
|
| Cell Assay |
KUN50259 is assessed in cell-based assays to evaluate its effects on DAAO activity in a cellular context. Cells expressing DAAO are treated with the compound, and the inhibition of DAAO activity is measured. This can be done by assessing the levels of D-amino acids or by using a reporter system for DAAO activity. However, specific cell-based assay protocols are not extensively documented.
|
| Animal Protocol |
KUN50259 is administered in animal models to evaluate its effects on DAAO activity and behavior. It has potential applications in models of schizophrenia and other disorders. However, specific animal study protocols are not extensively documented. The compound is typically formulated for in vivo administration using DMSO or other suitable vehicles.
|
| ADME/Pharmacokinetics |
KUN50259 has a molecular formula of C7H5FN2O and a molecular weight of 152.13. Its CAS number is 2065250-25-9. The compound is a solid powder. It should be stored as a powder at -20°C for up to 3 years. It is also known as DAAO inhibitor-1 and Compound 35.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for KUN50259. The compound is for research use only and is not intended for human therapeutic use. It is a potent DAAO inhibitor used as a pharmacological tool to study the role of DAAO in neurological and psychiatric disorders.
|
| Additional Infomation |
KUN50259 is a potent inhibitor of D-amino acid oxidase (DAAO). It is also known as DAAO inhibitor-1 and Compound 35. It is used in research to study the role of DAAO in various neurological and psychiatric disorders. The compound is not approved for clinical use.
|
| Molecular Formula |
C7H5FN2O
|
|---|---|
| Molecular Weight |
152.125804662704
|
| Exact Mass |
152.038
|
| CAS # |
2065250-25-9
|
| Related CAS # |
2065250-25-9 ;
|
| PubChem CID |
24728218
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
1.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
185
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC2=C(C=C1F)NNC2=O
|
| InChi Key |
KBPHAHZMJXVUPU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H5FN2O/c8-4-1-2-5-6(3-4)9-10-7(5)11/h1-3H,(H2,9,10,11)
|
| Chemical Name |
6-fluoro-1,2-dihydroindazol-3-one
|
| Synonyms |
DAAO inhibitor-1 DAAO inhibitor-1 DAAO inhibitor1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~821.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (13.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (13.67 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (13.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5733 mL | 32.8666 mL | 65.7333 mL | |
| 5 mM | 1.3147 mL | 6.5733 mL | 13.1467 mL | |
| 10 mM | 0.6573 mL | 3.2867 mL | 6.5733 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
